Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug

A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]

Read full article at https://wccftech.com/broadside-against-eli-lilly-and-company-novo-nordisk-hypes-the-20-reduction-in-death-risk-offered-by-its-glp-1-weight-loss-drug/